MARKET

MNKD

MNKD

MannKind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.506
-0.164
-3.51%
Opening 12:43 09/16 EDT
OPEN
4.700
PREV CLOSE
4.670
HIGH
4.700
LOW
4.465
VOLUME
1.77M
TURNOVER
--
52 WEEK HIGH
6.25
52 WEEK LOW
1.771
MARKET CAP
1.12B
P/E (TTM)
-12.4303
1D
5D
1M
3M
1Y
5Y
Mannkind Corporation Participating at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Pre...
GlobeNewswire · 1d ago
BRIEF-United Therapeutics Presents Tyvaso DPI Breeze Clinical Data At European Respiratory Society International Congress 2021
reuters.com · 09/07 10:42
MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
WESTLAKE VILLAGE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced tod...
GlobeNewswire · 09/07 10:05
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
United Therapeutics Corporation (Nasdaq: UTHR) today presented new clinical data from the BREEZE study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Cong...
PR Newswire · 09/07 10:00
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021
and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension () at the European Respiratory Society () ...
PR Newswire - PRF · 08/24 10:00
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Last week saw the newest quarterly earnings release from MannKind Corporation ( NASDAQ:MNKD ), an important milestone...
Simply Wall St. · 08/14 07:40
MannKind Files For U.S. Patent Application Titled 'DRY POWDER DRUG DELIVERY SYSTEM'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6226&p=125&f=G&l=50&d=PG01&S1=20210812.PD.&OS=PD/20210812&RS=PD/20210812
Benzinga · 08/12 13:57
MannKind Files For U.S. Patent Application Titled 'Use of Ultrarapid Acting Insulin'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6323&p=127&f=G&l=50&d=PG01&S1=20210812.PD.&OS=PD/20210812&RS=PD/20210812
Benzinga · 08/12 13:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNKD. Analyze the recent business situations of MannKind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNKD stock price target is 6.17 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 229
Institutional Holdings: 114.75M
% Owned: 45.96%
Shares Outstanding: 249.66M
TypeInstitutionsShares
Increased
53
11.34M
New
29
6.94M
Decreased
39
12.46M
Sold Out
23
3.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.09%
Pharmaceuticals & Medical Research
-0.43%
Key Executives
Non-Executive Chairman/Independent Director
James Shannon
Chief Executive Officer/Director
Michael Castagna
Chief Financial Officer
Steven Binder
Chief Human Resource Officer
Stuart Tross
Executive Vice President/General Counsel/Secretary
David Thomson
Chief Technology Officer
Joseph Kocinsky
Independent Director
Ronald Consiglio
Independent Director
Michael Friedman
Independent Director
Jennifer Grancio
Independent Director
Anthony Hooper
Independent Director
Sabrina Kay
Independent Director
Kent Kresa
Independent Director
Christine Mundkur
No Data
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

Webull offers kinds of MannKind Corporation stock information, including NASDAQ:MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.